GADD45A methylation predicts poor overall survival in acute myeloid leukemia and is associated with IDH1/2 and DNMT3A mutations

Leukemia

Volumn 27, Issue 7, 2013, Pages 1588-1592

  Perugini, M ^a,b,c   Iarossi, D G ^a   Kok, C H ^a,c   Cummings, N ^d   Diakiw, S M ^a   Brown, A L ^a,c   Danner, S ^b   Bardy, P ^e   Bik To, L ^a,b,c   Wei, A H ^d   Lewis, I D ^a,b,c   D'Andrea, R J ^a,c,e  

^a CENTRE FOR CANCER BIOLOGY   (Australia)

^b ROYAL ADELAIDE HOSPITAL   (Australia)

^c UNIVERSITY OF ADELAIDE   (Australia)

^d ALFRED HOSPITAL   (Australia)

^e QUEEN ELIZABETH HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CD135 ANTIGEN; CPG OLIGODEOXYNUCLEOTIDE; CYTARABINE; CYTOTOXIC AGENT; DNA METHYLTRANSFERASE 3A; GENOMIC DNA; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45; IDARUBICIN; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; PROTEIN GADD45A; RETINOIC ACID; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CLINICAL ASSESSMENT; COHORT ANALYSIS; CYTOGENETICS; DNA METHYLATION; DRUG EFFICACY; DRUG MEGADOSE; EPIGENETICS; GENE SILENCING; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENOTYPE; HISTOPATHOLOGY; HUMAN; IN VITRO STUDY; LETTER; OVERALL SURVIVAL; PHENOTYPE; PRIORITY JOURNAL; RISK FACTOR; SOMATIC MUTATION; THROMBOCYTE COUNT; TREATMENT RESPONSE; TUMOR SUPPRESSOR GENE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CELL CYCLE PROTEINS; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA METHYLATION; FEMALE; GENETIC TESTING; HUMANS; ISOCITRATE DEHYDROGENASE; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MUTATION; NUCLEAR PROTEINS; YOUNG ADULT;

EID: 84880312982     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2012.346     Document Type: Letter

References (16)

1. Figueroa ME, Abdel-Wahab O, Lu C, Ward PS, Patel J, Shih A et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer cell 2010; 18: 553-567.
2. Renneville A, Boissel N, Nibourel O, Berthon C, Helevaut N, Gardin C et al. Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association. Leukemia 2012; 26: 1247-1254.
3. Metzeler KH, Maharry K, Radmacher MD, Mrozek K, Margeson D, Becker H et al. TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol 2011; 29: 1373-1381.
4. Shih AH, Abdel-Wahab O, Patel JP, Levine RL. The role of mutations in epigenetic regulators in myeloid malignancies. Nat Rev 2012; 12: 599-612.
5. Barreto G, Schafer A, Marhold J, Stach D, Swaminathan SK, Handa V et al. Gadd45a promotes epigenetic gene activation by repair-mediated DNA demethylation. Nature 2007; 445: 671-675.
6. Liebermann D, Tront JS, Sha X, Mukherjee K, Mohamed-Hadley A, Hoffman B. Gadd45 stress sensors in malignancy and leukemia. Crit Rev Oncog 2011; 16: 129-140.
7. Perugini M, Kok CH, Brown AL, Wilkinson CR, Salerno DG, Young SM et al. Repression of Gadd45alpha by activated FLT3 and GM-CSF receptor mutants contributes to growth, survival and blocked differentiation. Leukemia 2009; 23: 729-738.
8. Satoh Y, Matsumura I, Tanaka H, Harada H, Harada Y, Matsui K et al. C-terminal mutation of RUNX1 attenuates the DNA-damage repair response in hematopoietic stem cells. Leukemia 2011; 26: 303-311.
9. Wang W, Huper G, Guo Y, Murphy SK, Olson Jr JA, Marks JR. Analysis of methylation- sensitive transcriptome identifies GADD45a as a frequently methylated gene in breast cancer. Oncogene 2005; 24: 2705-2714.
10. Ramachandran K, Gopisetty G, Gordian E, Navarro L, Hader C, Reis IM et al. Methylation-mediated repression of GADD45alpha in prostate cancer and its role as a potential therapeutic target. Cancer Res 2009; 69: 1527-1535.
11. Al-Romaih K, Sadikovic B, Yoshimoto M, Wang Y, Zielenska M, Squire JA. Decitabine- induced demethylation of 5' CpG island in GADD45A leads to apoptosis in osteosarcoma cells. Neoplasia 2008; 10: 471-480.
12. Zhang W, Hoffman B, Liebermann DA. Ectopic expression of MyD118/Gadd45/CR6 (Gadd45beta/alpha/gamma) sensitizes neoplastic cells to genotoxic stressinduced apoptosis. Int J Oncol 2001; 18: 749-757.
13. Cashen AF, Schiller GJ, O'Donnell MR, Multicenter DiPersioJF. phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. J Clin Oncol 2010; 28: 556-561.
14. Quintas-Cardama A, Ravandi F, Liu-Dumlao T, Brandt M, Faderl S, Pierce S et al. Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia. Blood 2012; 120: 4840-4845.
15. Scandura JM, Roboz GJ, Moh M, Morawa E, Brenet F, Bose JR et al. Phase 1 study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AML. Blood 2011; 118: 1472-1480.
16. Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 2010; 116: 354-365.